A Randomized, Double-Blind, Parallel, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis
Latest Information Update: 08 Nov 2022
At a glance
- Drugs Dupilumab (Primary)
- Indications Eosinophilic oesophagitis
- Focus Proof of concept; Therapeutic Use
- Sponsors Regeneron Pharmaceuticals; Sanofi
- 27 Sep 2022 Results comparing dupilumab pharmacokinetics from studies (POC; NCT02379052 & LIBERTY EoE TREETstudy (NCT03633617)) to previous dupilumab trials in atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis, presented at the 2022 American College of Clinical Pharmacology Annual Meeting.
- 27 Oct 2021 Results assessing relationship esophageal intraepithelial eosinophil count (eos/hpf) and EREFS total score, inflammation and remodeling subscores, and individual components scores in patients with EoE receiving placebo in the phase 2 POC study and part A of the phase 3 LIBERTY TREET study, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021.
- 27 Oct 2021 Results assessing Histology Scoring System (HSS) components correlate with inflammatory or remodeling EREFS components in EoE patients receiving placebo in 2 trials; 12-week phase 2 proof-of-concept (POC; NCT02379052) in adults and 24-week part A of the 3-part, phase 3 TREET (P3PA; NCT03633617) in adults and adolescents, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021.